CA2895162C - Methods and compositions for inhibiting cnksr1 - Google Patents

Methods and compositions for inhibiting cnksr1 Download PDF

Info

Publication number
CA2895162C
CA2895162C CA2895162A CA2895162A CA2895162C CA 2895162 C CA2895162 C CA 2895162C CA 2895162 A CA2895162 A CA 2895162A CA 2895162 A CA2895162 A CA 2895162A CA 2895162 C CA2895162 C CA 2895162C
Authority
CA
Canada
Prior art keywords
cancer
compound
kras
c4alkyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2895162A
Other languages
English (en)
French (fr)
Other versions
CA2895162A1 (en
Inventor
D. Lynn Kirkpatrick
Martin INDARTE
Nathan T. Ihle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHUSIS THERAPEUTICS Inc
Original Assignee
PHUSIS THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHUSIS THERAPEUTICS Inc filed Critical PHUSIS THERAPEUTICS Inc
Publication of CA2895162A1 publication Critical patent/CA2895162A1/en
Application granted granted Critical
Publication of CA2895162C publication Critical patent/CA2895162C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA2895162A 2012-12-14 2013-12-16 Methods and compositions for inhibiting cnksr1 Active CA2895162C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737658P 2012-12-14 2012-12-14
US61/737,658 2012-12-14
PCT/US2013/075505 WO2014093988A2 (en) 2012-12-14 2013-12-16 Methods and compositions for inhibiting cnksr1

Publications (2)

Publication Number Publication Date
CA2895162A1 CA2895162A1 (en) 2014-06-19
CA2895162C true CA2895162C (en) 2021-03-09

Family

ID=50935099

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2895162A Active CA2895162C (en) 2012-12-14 2013-12-16 Methods and compositions for inhibiting cnksr1

Country Status (7)

Country Link
US (1) US9340532B2 (https=)
EP (1) EP2931280B1 (https=)
JP (1) JP6357292B2 (https=)
AU (1) AU2013358876B2 (https=)
CA (1) CA2895162C (https=)
MX (2) MX372739B (https=)
WO (1) WO2014093988A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093988A2 (en) 2012-12-14 2014-06-19 Phusis Therapeutics, Inc. Methods and compositions for inhibiting cnksr1
US10227356B2 (en) * 2015-04-20 2019-03-12 Phusis Therapeutics, Inc. Compounds, compositions and methods for inhibiting CNKSR1
WO2018125983A1 (en) 2016-12-30 2018-07-05 Mitobridge, Inc. Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
CN110698411B (zh) * 2018-07-09 2023-05-09 四川大学 一类4-(胺烷基)酞嗪-1-酮类化合物、其制备方法和用途
US20230312482A1 (en) * 2020-07-28 2023-10-05 Mirati Therapeutics, Inc. Sos1 inhibitors
US20240158386A1 (en) * 2021-03-02 2024-05-16 Icahn School Of Medicine At Mount Sinai Benzoxazolone inhibitors of inflammasomes
TW202319375A (zh) * 2021-08-19 2023-05-16 美商安進公司 用於製備丙烯酸酯化合物之無鈀方法
WO2024192873A1 (zh) * 2023-03-20 2024-09-26 杭州天玑济世生物科技有限公司 一类具有萘胺结构的小分子化合物的用途
CN116444477B (zh) * 2023-04-04 2026-01-02 宁波九胜创新医药科技有限公司 一种溴代胡椒环羧酸的制备方法及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA775563A (en) 1968-01-09 Frank W. Horner Limited Hypoglycemic thiadiazoles
GB828963A (en) 1956-08-03 1960-02-24 Rhone Poulenc Sa Pharmaceutical compositions containing 2-p-aminobenzenesulphonamido-5-t-butyl-1, 3, 4-thiadiazole
US3821222A (en) 1971-11-22 1974-06-28 Chevron Res Hydrocarbyl sulfenylmercapto pyrimidines
US4017489A (en) 1975-07-10 1977-04-12 The Goodyear Tire & Rubber Company Process of preparing unsymmetrical disulfides
DE2556011A1 (de) 1975-12-12 1977-06-23 Merck Patent Gmbh Disulfide
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
GB2152497B (en) 1983-11-28 1987-08-05 Otsuka Kagaku Kk Process for the preparation of azetidinone derivatives
FR2573077B1 (fr) 1984-11-13 1987-02-13 Sanofi Sa Nouveaux derives thiosulfonates, leur procede de preparation ainsi que les compositions pharmaceutiques les contenant
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4990523A (en) 1989-06-19 1991-02-05 A. H. Robins Company, Incorporated Treatment of chronic inflammatory joint disease with arylsulfonamides
GB9507415D0 (en) * 1994-06-08 1995-05-31 Zylepsis Ltd Production and uses of caffeic acid and derivatives thereof
US6139875A (en) 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
US20040106540A1 (en) 2001-04-10 2004-06-03 Barnett Stanley F Method of treating cancer
KR100955015B1 (ko) * 2001-08-15 2010-04-28 이코스 코포레이션 2ｈ-프탈라진-1-온 및 이것의 사용 방법
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
EP1496981A2 (en) 2002-04-08 2005-01-19 Merck & Co., Inc. Method of treating cancer
GB0215823D0 (en) * 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
DE602004032345D1 (de) 2003-06-24 2011-06-01 Isis Innovation Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen
JP2009513523A (ja) 2003-07-08 2009-04-02 ノバルティス アクチエンゲゼルシャフト ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物
DE602005015838D1 (de) 2004-03-19 2009-09-17 Tapemark Co Thermoplastische filme und herstellungsverfahren dafür
WO2005097758A1 (en) 2004-03-26 2005-10-20 Amphora Discovery Corporation Certain triazole-based compounds, compositions, and uses thereof
SE0402635D0 (sv) 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
EP1937659B1 (en) 2005-10-06 2010-11-10 Sanofi-Aventis Cyclic n-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
US20070213378A1 (en) 2006-03-10 2007-09-13 Lymphosign Inc. Compounds for modulating cell proliferation, compositions and methods related thereto
WO2007114926A2 (en) 2006-04-04 2007-10-11 The Regents Of The University Of California Kinase antagonists
EP2104489A2 (en) 2006-12-26 2009-09-30 FemmePharma Holding Company, Inc. Topical administration of danazol
MX2010011258A (es) 2008-04-14 2011-06-20 Univ Texas Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
WO2010085968A1 (en) * 2008-12-30 2010-08-05 European Molecular Biology Laboratory (Embl) Toluidine sulfonamides and their use as hif-inhibitors
WO2010118063A2 (en) * 2009-04-06 2010-10-14 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
CA2773561A1 (en) * 2009-09-14 2011-03-17 Phusis Therapeutics Inc. Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
JP2014510151A (ja) * 2011-04-05 2014-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ（ｔｒａｋｉｎａｓｅ）阻害剤として有用なアミノピラジン化合物
WO2014093988A2 (en) 2012-12-14 2014-06-19 Phusis Therapeutics, Inc. Methods and compositions for inhibiting cnksr1

Also Published As

Publication number Publication date
EP2931280B1 (en) 2018-02-14
JP2016508969A (ja) 2016-03-24
EP2931280A4 (en) 2016-06-01
US20150307482A1 (en) 2015-10-29
MX2015007608A (es) 2016-04-13
AU2013358876B2 (en) 2018-05-10
CA2895162A1 (en) 2014-06-19
MX372739B (es) 2020-05-06
WO2014093988A2 (en) 2014-06-19
WO2014093988A3 (en) 2014-08-07
AU2013358876A1 (en) 2014-06-19
EP2931280A2 (en) 2015-10-21
US9340532B2 (en) 2016-05-17
JP6357292B2 (ja) 2018-07-11
MX393754B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
CA2895162C (en) Methods and compositions for inhibiting cnksr1
JP7789832B2 (ja) がんを治療するための組成物及び方法
Li et al. Discovery of N 1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo [2, 3-d] pyrimidin-2-yl) amino) phenyl)-N 8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
KR102057358B1 (ko) Tor 키나제 억제제를 사용한 암의 치료
JP5711813B2 (ja) βセクレターゼ（ＢＡＣＥ）の阻害剤として有用な５，６−ジヒドロ−２Ｈ−［１，４］オキサジン−３−イル−アミン誘導体
ES2668279T3 (es) Tratamiento del cáncer con inhibidores de la cinasa TOR
ES2678250T3 (es) Tratamiento del cáncer con inhibidores de quinasa TOR
US10183019B2 (en) Treatment of cancer with dihydropyrazino-pyrazines
ES2780382T3 (es) Derivados de pirazolopirimidina
FR2929851A1 (fr) Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
JP2019508404A (ja) 癌患者の層別化および癌治療のための化合物、組成物および方法
BR122021004509B1 (pt) Sais de inibidor de pi3k e processos para seu preparo
JP6708849B1 (ja) ピロロピリジン誘導体化合物、その製造方法及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防または治療のための薬学的組成物
TWI458730B (zh) 新穎２，３－二氫－１Ｈ－咪唑并｛１，２－ａ｝嘧啶－５－酮衍生物，其製法及其醫藥用途
JP2024535128A (ja) 新規治療
CA2983260C (en) Sulfonamide compounds, compositions and methods for inhibiting cnksr1
US20230144901A1 (en) Sortilin antagonists for use in the treatment of diabetic retinopathy
US20240391928A1 (en) Compositions for the treatment of food and chemical addiction and methods of making and using same
JP2023513016A (ja) Ｎｅｋ２阻害剤としてのアミノピリミジニルアミノベンゾニトリル誘導体
BR112017018312B1 (pt) Sais de inibidor de pi3k, composições que as compreende, seu uso, processos para seu preparo e método de inibição de uma atividade de uma quinase pi3k

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181214

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251124